EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study

Santi Nolasco iD, Evelina Fagone, Raffaele Campisi, Andrea Portacci iD, Giulia Scioscia, Corrado Pelaia, Angelantonio Maglio iD, Claudio Candia, Vitaliano Nicola Quaranta iD, Isabella Carrieri, Alessandro Saglia, Alessandro Vatrella und 8 weitere

Allergy · 2025

DOI: 10.1111/all.70071 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Allergy, 2025. Verfasst von Santi Nolasco und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Asthma, Receptors, Adrenergic, beta-2, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background β 2 ‐adrenergic signaling promotes airway smooth muscle relaxation and limits the release of pro‐inflammatory mediators by immune cells. The rs1042713 polymorphism encodes a glycine‐to‐arginine substitution (Arg16Gly) that enhances β 2 ‐receptor downregulation. We investigated the association of this polymorphism with the risk of severe eosinophilic asthma and its impact on the long‐term effectiveness of mepolizumab and clinical remission.

Methods

Genotypes from 102 patients with severe eosinophilic asthma receiving mepolizumab were compared with those from 31 individuals with mild asthma and 20 healthy controls. The severe‐asthma cohort was followed for up to 24 months, and clinical data were collected at baseline and after 3, 6, 12, and 24 months of treatment. Analyses were stratified by Arg/Arg, Arg/Gly, and Gly/Gly genotypes.

Results

Each additional Arg16 allele increased the odds of severe eosinophilic asthma by 2.61‐fold (95% CI 1.48–4.59; p = 0.0001) relative to mild asthma and by 3.61‐fold (95% CI 1.78–7.35; p < 0.0001) relative to healthy controls. Over 24 months of mepolizumab treatment, Arg/Arg patients had an increased risk of exacerbations (HR 2.3 [95% CI 1.03–5.20]; p = 0.0414) and poorer asthma control compared with Gly/Gly patients (ACT ≥ 20: 72.4% vs. 100%, p = 0.0308). Gly/Gly patients also experienced less decline in lung function. By month 24, each additional Gly16 allele increased the odds of achieving clinical remission by 2.86‐fold (95% CI 1.20–6.81; p = 0.0170), defined as no annual exacerbations, no OCS, and ACT ≥ 20, and by 3.06‐fold (95% CI 1.34–6.96; p = 0.0080) when including an FEV 1 decline ≤ 5% from baseline.

Conclusions

The Arg16 allele of the rs1042713 polymorphism increases the risk of severe eosinophilic asthma and may reduce the long‐term efficacy of mepolizumab, whereas the Gly16 allele appears to confer better outcomes and higher remission rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaReceptors, Adrenergic, beta-2Antibodies, Monoclonal, HumanizedPolymorphism, Single NucleotideAnti-Asthmatic AgentsEosinophiliaPolymorphism, GeneticHumansFemaleMaleAdultGenotypeMiddle AgedTreatment OutcomeAllelesRemission InductionSeverity of Illness IndexEosinophilsAmino Acid Substitution

Stichwörter der Autor:innen

Arg16Glymepolizumabremissionsevere asthmaβ2‐adrenergic receptor

Substanzen

mepolizumabReceptors, Adrenergic, beta-2Antibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, Catania, Italy.
  • Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
  • Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.

ORCID-Profile: Santi Nolasco, Andrea Portacci, Angelantonio Maglio, Vitaliano Nicola Quaranta

Zitieren

APA

Nolasco, S., Fagone, E., Campisi, R., Portacci, A., Scioscia, G., Pelaia, C., Maglio, A., Candia, C., Quaranta, V. N., Carrieri, I., Saglia, A., Vatrella, A., Pelaia, G., Vancheri, C., Foschino Barbaro, M. P., D'Amato, M., Carpagnano, G. E., Crimi, N., Crimi, C., & Southern Italy Network on Severe Asthma Therapy (2025). Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. https://doi.org/10.1111/all.70071

Vancouver

Nolasco S, Fagone E, Campisi R, Portacci A, Scioscia G, Pelaia C, et al. Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. 2025. doi:10.1111/all.70071

BibTeX
@article{Nolasco2025,
  author = {Nolasco, Santi and Fagone, Evelina and Campisi, Raffaele and Portacci, Andrea and Scioscia, Giulia and Pelaia, Corrado and Maglio, Angelantonio and Candia, Claudio and Quaranta, Vitaliano Nicola and Carrieri, Isabella and Saglia, Alessandro and Vatrella, Alessandro and Pelaia, Girolamo and Vancheri, Carlo and Foschino Barbaro, Maria Pia and D'Amato, Maria and Carpagnano, Giovanna Elisiana and Crimi, Nunzio and Crimi, Claudia and Southern Italy Network on Severe Asthma Therapy, Southern Italy Network on Severe Asthma Therapy},
  title = {Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.70071}
}
Kostenlos starten →